T2 Biosystems Inc
NASDAQ:TTOO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Rouchon Industries Inc
OTC:RCHN
|
US |
T2 Biosystems Inc
Research & Development
T2 Biosystems Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
T2 Biosystems Inc
NASDAQ:TTOO
|
Research & Development
-$12.5m
|
CAGR 3-Years
15%
|
CAGR 5-Years
4%
|
CAGR 10-Years
4%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
T2 Biosystems Inc
Glance View
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 182 full-time employees. The company went IPO on 2014-08-07. The firm is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The firm is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common blood stream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis.
See Also
What is T2 Biosystems Inc's Research & Development?
Research & Development
-12.5m
USD
Based on the financial report for Sep 30, 2024, T2 Biosystems Inc's Research & Development amounts to -12.5m USD.
What is T2 Biosystems Inc's Research & Development growth rate?
Research & Development CAGR 10Y
4%
Over the last year, the Research & Development growth was 17%. The average annual Research & Development growth rates for T2 Biosystems Inc have been 15% over the past three years , 4% over the past five years , and 4% over the past ten years .
